Cargando…

The 2020 NBA Orthobiologics Consensus Statement

This 2020 NBA Orthobiologics Consensus Statement provides a concise summary of available literature and practical clinical guidelines for team physicians and players. We recognize that orthobiologic injections are a generally safe treatment modality with a significant potential to reduce pain and ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Cole, Brian J., Gilat, Ron, DiFiori, John, Rodeo, Scott A., Bedi, Asheesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114275/
https://www.ncbi.nlm.nih.gov/pubmed/34017878
http://dx.doi.org/10.1177/23259671211002296
_version_ 1783691028554842112
author Cole, Brian J.
Gilat, Ron
DiFiori, John
Rodeo, Scott A.
Bedi, Asheesh
author_facet Cole, Brian J.
Gilat, Ron
DiFiori, John
Rodeo, Scott A.
Bedi, Asheesh
author_sort Cole, Brian J.
collection PubMed
description This 2020 NBA Orthobiologics Consensus Statement provides a concise summary of available literature and practical clinical guidelines for team physicians and players. We recognize that orthobiologic injections are a generally safe treatment modality with a significant potential to reduce pain and expedite early return to play in specific musculoskeletal injuries. The use of orthobiologics in sports medicine to safely reduce time loss and reinjury is of considerable interest, especially as it relates to the potential effect on a professional athlete. While these novel substances have potential to enhance healing and regeneration of injured tissues, there is a lack of robust data to support their regular use at this time. There are no absolutes when considering the implementation of orthobiologics, and unbiased clinical judgment with an emphasis on player safety should always prevail. Current best evidence supports the following:  Key Points;  There is support for the use of leukocyte-poor platelet-rich plasma in the treatment of knee osteoarthritis.  There is support for consideration of using leukocyte-rich platelet-rich plasma for patellar tendinopathy.  The efficacy of using mesenchymal stromal cell injections in the management of joint and soft tissue injuries remains unproven at this time. There are very few data to suggest that current cell therapy treatments lead to any true functional tissue regeneration. Meticulous and sterile preparation guidelines must be followed to minimize the risk for infection and adverse events if these treatments are pursued. Given the high variability in orthobiologic formulations, team physicians must stay up-to-date with the most recent peer-reviewed literature and orthobiologic preparation protocols for specific injuries. Evidence-based treatment algorithms are necessary to identify the optimal orthobiologic formulations for specific tissues and injuries in athletes. Changes in the regulatory environment and improved standardization are required given the exponential increase in utilization as novel techniques and substances are introduced into clinical practice.
format Online
Article
Text
id pubmed-8114275
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81142752021-05-19 The 2020 NBA Orthobiologics Consensus Statement Cole, Brian J. Gilat, Ron DiFiori, John Rodeo, Scott A. Bedi, Asheesh Orthop J Sports Med Article This 2020 NBA Orthobiologics Consensus Statement provides a concise summary of available literature and practical clinical guidelines for team physicians and players. We recognize that orthobiologic injections are a generally safe treatment modality with a significant potential to reduce pain and expedite early return to play in specific musculoskeletal injuries. The use of orthobiologics in sports medicine to safely reduce time loss and reinjury is of considerable interest, especially as it relates to the potential effect on a professional athlete. While these novel substances have potential to enhance healing and regeneration of injured tissues, there is a lack of robust data to support their regular use at this time. There are no absolutes when considering the implementation of orthobiologics, and unbiased clinical judgment with an emphasis on player safety should always prevail. Current best evidence supports the following:  Key Points;  There is support for the use of leukocyte-poor platelet-rich plasma in the treatment of knee osteoarthritis.  There is support for consideration of using leukocyte-rich platelet-rich plasma for patellar tendinopathy.  The efficacy of using mesenchymal stromal cell injections in the management of joint and soft tissue injuries remains unproven at this time. There are very few data to suggest that current cell therapy treatments lead to any true functional tissue regeneration. Meticulous and sterile preparation guidelines must be followed to minimize the risk for infection and adverse events if these treatments are pursued. Given the high variability in orthobiologic formulations, team physicians must stay up-to-date with the most recent peer-reviewed literature and orthobiologic preparation protocols for specific injuries. Evidence-based treatment algorithms are necessary to identify the optimal orthobiologic formulations for specific tissues and injuries in athletes. Changes in the regulatory environment and improved standardization are required given the exponential increase in utilization as novel techniques and substances are introduced into clinical practice. SAGE Publications 2021-05-06 /pmc/articles/PMC8114275/ /pubmed/34017878 http://dx.doi.org/10.1177/23259671211002296 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Article
Cole, Brian J.
Gilat, Ron
DiFiori, John
Rodeo, Scott A.
Bedi, Asheesh
The 2020 NBA Orthobiologics Consensus Statement
title The 2020 NBA Orthobiologics Consensus Statement
title_full The 2020 NBA Orthobiologics Consensus Statement
title_fullStr The 2020 NBA Orthobiologics Consensus Statement
title_full_unstemmed The 2020 NBA Orthobiologics Consensus Statement
title_short The 2020 NBA Orthobiologics Consensus Statement
title_sort 2020 nba orthobiologics consensus statement
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114275/
https://www.ncbi.nlm.nih.gov/pubmed/34017878
http://dx.doi.org/10.1177/23259671211002296
work_keys_str_mv AT colebrianj the2020nbaorthobiologicsconsensusstatement
AT gilatron the2020nbaorthobiologicsconsensusstatement
AT difiorijohn the2020nbaorthobiologicsconsensusstatement
AT rodeoscotta the2020nbaorthobiologicsconsensusstatement
AT bediasheesh the2020nbaorthobiologicsconsensusstatement
AT colebrianj 2020nbaorthobiologicsconsensusstatement
AT gilatron 2020nbaorthobiologicsconsensusstatement
AT difiorijohn 2020nbaorthobiologicsconsensusstatement
AT rodeoscotta 2020nbaorthobiologicsconsensusstatement
AT bediasheesh 2020nbaorthobiologicsconsensusstatement